1 Day Understanding Key Factors When Working with the FDA Training Course: Streamlining Drug Application Processes, Specifically for NDAs, Generics, and Biosimilars (ONLINE EVENT: May 12, 2026)

The course offers significant market opportunities by equipping senior and project managers with essential FDA-related insights, enhancing team interaction, and streamlining drug application processes, specifically for NDAs, generics, and biosimilars, making it ideal for time-constrained professionals.


Dublin, April 10, 2026 (GLOBE NEWSWIRE) -- The "US FDA - Understanding Key Factors When Working with the FDA (May 12, 2026)" training has been added to ResearchAndMarkets.com's offering.

This course has been designed to provide an essential overview of the key factors when working with the FDA.

It will equip senior managers and project managers with pivotal information to enable them to interact with their teams and ask critical questions to ensure the best outcomes when making applications to the FDA.

The programme will provide an overview of the US FDA's organisational divisions and examine the drug development regulations. It will provide a valuable guide through the review options and discuss the New Drug Application (NDA) process and how the FDA deals with Generics and Biosimilars.

For those short on time this course is for you, as you will receive a focused and comprehensive overview of the key strategic considerations when making applications to the FDA.

Who Should Attend:

  • Pharmaceutical and Biopharmaceutical Starts-ups
  • Pharmaceutical Executives
  • Senior Management
  • Business Development Managers
  • Regulatory Strategists
  • Project Managers
  • All those who wish to broaden their knowledge on working with the FDA

Key Topics Covered:

  • Overview of the US Food and Drug Administration (FDA)
  • Examining the Drug Development Regulations in the US
  • FDA Meetings
  • Evaluation of FDA Review Options
  • Reviewing the New Drug Application (NDA) process / Biologics Licensing Application (BLA) Process
  • Understand ANDA (Generics) and 351K (Biosimilars) Applications
  • Review the Importance of Lifecycle Management in the US

Speakers

Andrew Willis

Andrew Willis is an independent consultant providing expert advice and training on global regulatory solutions and pharmaceutical development. Previously, he worked for Catalent Pharma Solutions as VP Regulatory Affairs & Consulting Services, where he was head of a team of internal and external regulatory affairs consultants.

He qualified as a Chemist from the University of Glamorgan, after which he furthered his understanding of pharmaceutical development, working as a research chemist with Parke Davis. He had 10 years manufacturing and analytical experience prior to entering regulatory affairs as a Senior Executive Officer with responsibility for submission of European MAAs and project management of development programs.

He has over 30 years' pharmaceutical experience with extensive knowledge in the development and manufacture of sterile, solid oral, inhalation, topical and biotech pharmaceutical products. These experiences have allowed knowledge of many biotech products requirements with experiences of growth hormones and multiple cancer treatments, including development and clinical registration of the first genetically modified live bacterium for such treatment.

He has extensive experience of major European and US regulatory projects, in the clinical and marketing authorisation stages, and has significant experience in coordinating and managing meetings with European and US Health Authorities.

For more information about this training visit https://www.researchandmarkets.com/r/3uuaxi

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

 

Coordonnées

GlobeNewswire